Track BioXcel Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioXcel Therapeutics, Inc. BTAI · Stock Open BioXcel Therapeutics, Inc. in new tab

0.0739 USD
EPS
-2.58
P/B
-0.02
Beta
0.19
Target Price
18.33 USD
Loading chart...
Key Metrics
EPS-2.58
Book Value-3.69
Price to Book-0.02
% Insiders3.601%
Growth
Revenue Growth0.52%
Estimates
Forward P/E-0.03
Forward EPS-2.14
Target Mean Price18.33

DCF valuation

Model fair value for BioXcel Therapeutics, Inc. (BTAI)
Result
Sign in to run the valuation for BTAI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
consensus None · mean target 18.33 USD (low 5.00, high 38.00)
Low 5.00
Mean 18.33
High 38.00
Price 0.0739
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

BioXcel Therapeutics, Inc. Logo BioXcel Therapeutics, Inc. Analysis (BTAI)

United States Health Care Official Website Stock

Is BioXcel Therapeutics, Inc. a good investment? BioXcel Therapeutics, Inc. (BTAI) is currently trading at 0.0739 USD. Market analysts have a consensus price target of 18.33 USD. This suggests a potential upside from current levels.

Investor FAQ

Does BioXcel Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioXcel Therapeutics, Inc.?

BioXcel Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Exchange Ticker
NMS (United States) BTAI
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 10, 2025 1:16
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion